Abstract Library

#2121 Phase II Study of Temozolomide Monotherapy in Patients of Neuroendocrine Carcinoma with Resistant to Platinum-Based Chemotherapy

Introduction: Neuroendocrine carcinomas (NEC) (high grade Ki67 > 20%) were poor prognostic and lethal disease. Platinum-based chemotherapy is usually chosen as a first line treatment for advanced NEC, however, this efficacy is temporary and there is no standard second-line treatment yet. Temozolomide is a good candidate, however it was not approved for NEC by Japanese authorities.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Ichikawa Y, Kobayashi N, Tokuhisa M, Goto A, Hiroshima Y,

Keywords: Neuroendocrine Carcinoma, Temozolomide,

#1788 Prospective Observational Study 1 on the Prognosis of Patients with Unresectable Advanced Gastrointestinal and Pancreatic Neuroendocrine Tumors (PROP-UP 1 Study) in Japan

Introduction: No previous observational studies on the prognosis of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) [pancreatic neuroendocrine neoplasms (PNENs) and gastrointestinal neuroendocrine neoplasms (GI-NENs)] exist in Japan.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Toriyama K, Hijioka S, Komoto I, Kobayashi N, Okusaka T,

Keywords: prop-up, japan, gep-nen,